Home > Publications database > The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops. > print

001     176967
005     20240229133726.0
024 7 _ |a 10.1038/s41467-021-25862-3
|2 doi
024 7 _ |a pmid:34584081
|2 pmid
024 7 _ |a altmetric:114166271
|2 altmetric
037 _ _ |a DKFZ-2021-02200
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Ottema, Sophie
|b 0
245 _ _ |a The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
260 _ _ |a [London]
|c 2021
|b Nature Publishing Group UK
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1634108639_29713
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Chromosomal rearrangements are a frequent cause of oncogene deregulation in human malignancies. Overexpression of EVI1 is found in a subgroup of acute myeloid leukemia (AML) with 3q26 chromosomal rearrangements, which is often therapy resistant. In AMLs harboring a t(3;8)(q26;q24), we observed the translocation of a MYC super-enhancer (MYC SE) to the EVI1 locus. We generated an in vitro model mimicking a patient-based t(3;8)(q26;q24) using CRISPR-Cas9 technology and demonstrated hyperactivation of EVI1 by the hijacked MYC SE. This MYC SE contains multiple enhancer modules, of which only one recruits transcription factors active in early hematopoiesis. This enhancer module is critical for EVI1 overexpression as well as enhancer-promoter interaction. Multiple CTCF binding regions in the MYC SE facilitate this enhancer-promoter interaction, which also involves a CTCF binding site upstream of the EVI1 promoter. We hypothesize that this CTCF site acts as an enhancer-docking site in t(3;8) AML. Genomic analyses of other 3q26-rearranged AML patient cells point to a common mechanism by which EVI1 uses this docking site to hijack enhancers active in early hematopoiesis.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Mulet-Lazaro, Roger
|0 0000-0003-0298-7948
|b 1
700 1 _ |a Erpelinck-Verschueren, Claudia
|0 0000-0002-3965-4488
|b 2
700 1 _ |a van Herk, Stanley
|0 0000-0002-8707-703X
|b 3
700 1 _ |a Havermans, Marije
|b 4
700 1 _ |a Arricibita Varea, Andrea
|b 5
700 1 _ |a Vermeulen, Michael
|b 6
700 1 _ |a Beverloo, H Berna
|b 7
700 1 _ |a Gröschel, Stefan
|0 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f
|b 8
|u dkfz
700 1 _ |a Haferlach, Torsten
|b 9
700 1 _ |a Haferlach, Claudia
|b 10
700 1 _ |a J Wouters, Bas
|b 11
700 1 _ |a Bindels, Eric
|b 12
700 1 _ |a Smeenk, Leonie
|0 0000-0001-7025-8515
|b 13
700 1 _ |a Delwel, Ruud
|b 14
773 _ _ |a 10.1038/s41467-021-25862-3
|g Vol. 12, no. 1, p. 5679
|0 PERI:(DE-600)2553671-0
|n 1
|p 5679
|t Nature Communications
|v 12
|y 2021
|x 2041-1723
909 C O |o oai:inrepo02.dkfz.de:176967
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2019
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2021-02-02
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-02
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NAT COMMUN : 2019
|d 2021-02-02
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-02
920 1 _ |0 I:(DE-He78)A380-20160331
|k A380
|l NWG Molekulare Leukämogenese
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A380-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21